Evidence map›Paper›PMID 39008063›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Evaluating [

Marco F Taddio, Suraj Doshi, Marwan Masri, Pauline Jeanjean, Firas Hikmat, Alana Gerlach, Lea Nyiranshuti, Ethan W Rosser, Dorthe Schaue, Elie Besserer-Offroy and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marco F TaddioDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. mtaddio@protonmail.com.ORCID 0000-0003-2477-5575
Suraj DoshiDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Marwan MasriDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Pauline JeanjeanDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Firas HikmatDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Alana GerlachDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Lea NyiranshutiDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Ethan W RosserDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Dorthe SchaueDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Elie Besserer-OffroyDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Giuseppe CarlucciDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Caius G RaduDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Johannes CzerninDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Katharina Lückerath *Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Christine E Mona *Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Jonsson Comprehensive Cancer Center Leader Vision AwardNCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015Prostate Cancer Foundation 19CHAL09Prostate Cancer Foundation TACT01 (2022)Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung P400PB_199263
6 · The paper itself

Abstract

purposeFibroblast Activation Protein (FAP) is an emerging theranostic target that is highly expressed on cancer-associated fibroblasts and on certain tumor cells including sarcoma. We investigated the anti-tumor efficacy of [

methods[

results[

conclusion[

Indexed as

EndopeptidasesSarcomaActiniumAnimalsCell Line, TumorFemaleFibroblast Activation Protein AlphaGelatinasesImmune Checkpoint InhibitorsMembrane ProteinsMiceSerine EndopeptidasesActiniumActinium-225EndopeptidasesFibroblast Activation Protein AlphaGelatinasesImmune Checkpoint InhibitorsMembrane ProteinsSerine EndopeptidasesActinium-225FAPI-46Fibroblast activation proteinImmune checkpoint blockadeSarcomaTheranostic

Identifiers

PMID39008063
PMCPMC11527918

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.